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Polymorphisms have been identified in the Xq28 locus as risk loci for rheumatoid arthritis (RA). Here, we investigated the
association between three polymorphisms in the Xq28 region containing TMEM187 and IRAK1 (rs13397, rs1059703, and rs1059702)
in two unstudied populations: Tunisian and French. The rs13397 G and rs1059703 T major alleles were significantly increased in
RA patients (𝑛 = 408) compared with age-matched controls (𝑛 = 471) in both Tunisian and French women. These results were
confirmed by a meta-analysis replication study including two independent Greek and Korean cohorts. The rs1059702 C major
allele was significantly associated with RA, only with French women. In the French population, the GTC haplotype displayed
a protective effect against RA, while the ATC, GCC, and GTT haplotypes conferred significant risk for RA. No association for
these haplotypes was found in the Tunisian population. Our results replicated for the first time the association of the three Xq28
polymorphismswith RA risk in Tunisian and French populations and suggested that RA susceptibility is associatedwithTMEM187-
IRAK1 polymorphisms in women. Our data further support the involvement of X chromosome in RA susceptibility and evidence
ethnicities differences that might be explained by differences in the frequencies of SE HLA-DRB1 alleles between both populations.
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1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease.
It is characterized by chronic destructive inflammation in
synovial joints. The prevalence of RA is about 1% in the adult
European population and is three times more common in
women than in men [1–4]. The aetiology of this complex dis-
ease is still poorly understood but is considered as a result of
interaction between susceptibility genes and environmental
factors [5].The genetic contribution toRAhas been estimated
to be about 50–60% [6], with the HLA (Human leukocyte
antigen) classes II molecules remaining the most powerful
known genetic factor [7]. There is extensive evidence for the
association between certain HLA-DRB1 alleles that contain a
conserved sequence of five amino acids (Q/RK/RRAA) in the
third hypervariable region of the DR𝛽1 chain, the so-called
shared epitope (SE), and RA susceptibility and severity [8–
10].
Genome-wide association studies (GWAS) and high-
density array Immunochip studies for single nucleotide poly-
morphisms (SNPs) genotyping of populations have identified
over 101 RA risk loci involved among individuals of European
and Asian ancestry [11–15]. Among these, IRAK1 (interleukin
1 receptor associated kinase) was the first X chromosome
locus reported as associated with RA susceptibility and is
thus of importance given the female predominance of the
disease. IRAK1 is a serine-threonine protein kinase and
an essential component of the toll/interleukin 1 receptor
(TIR) signaling pathway involved in the pathogen-mediated
inflammation [16]. Interestingly, the IRAK1 gene is located on
the Xq28 region that harbours several SNPs that have also
been associated with susceptibility to autoimmune diseases.
A recent case-control study investigated numerous SNPs
located on the Xq28 locus and identified rs1059703 and
rs1059702, encoding for pSer532Leu and pPhe196Ser, as two
IRAK1 SNPs most significantly associated with RA suscep-
tibility in Korean families [17]. These authors also showed
that the major haplotype (rs1059702 T and rs1059703 C) was
associated with increased IRAK1 activity. Of note, upstream
IRAK1 and within the Xq28 risk locus, Eyre et al. reported
the SNP rs13397 associated with RA risk among individuals
of northern European ancestry [13]. This polymorphism
is located within the TMEM187 gene, which encodes a
transmembrane protein of unknown function.
The relationship between these three polymorphisms on
the Xq28 region and RA risk in different population remains
unaddressed. Interestingly, a clear separation of different
ethnic and regional populations was evidenced when con-
sidering northern and southern Europe groups separately in
genetic studies, suggesting the existence of European popu-
lation genetic substructures [18]. In addition, there are also
clear differences between northern and southern Europe for
the main genetic risk factor for RA, HLA-DRB1∗04:04, and
DRB1∗04:01 genotypes being the most frequent in northern
populations, while HLA-DRB1∗10:01 andDRB1∗04:05 alleles
are more frequent in southern Europe, as well as in Maghreb
[19, 20]. Therefore, the present study aimed at investigating
the association between critical polymorphisms in Xq28,
from rs13397 (A/G) through rs1059703 (C/T) and rs1059702
(C/T) in the TMEM187 and IRAK1 locus, respectively, with
risk for RA in two not previously studied populations display-
ing different genetic background: Tunisian and French. We
also examined genetic differences for the HLA-DRB1 alleles
in both RA populations. Ameta-analysis including two other
independent cohorts was then performed to test the overall
effect of these TMEM187-IRAK1 polymorphisms on RA.
2. Patients and Methods
2.1. Study Subjects. For RA patients and healthy con-
trols, informed consents were provided in accordance with
national procedures. French studies were approved by local
human ethical committees: sample collection and analysis
(DC-2008-327) were approved by the “Cellule Bioe´thique,
Direction Ge´ne´rale pour la Recherche et l’Innovation, Min-
iste`re de l’Enseignement Supe´rieur et de la Recherche”
(Ministry Bioethics Unit) and by Comite´ de Protection des
Personnes SudMe´diterranne´e IV (ID RCB 2008-A01087-48).
Blood samples were collected from a total of 879 unrelated
female participants: 408 patients with RA and 471 controls
from Tunisia and France. Detailed size of Tunisian and
French cohort is shown in Table 1. RA patients fulfilled the
2010 ACR/EULAR classification criteria for RA [21]. The
clinical examination consisted of questionnaire and a physical
examination: age, geographical origin, family history, body
mass index, smoking habits, the presence of hypertension,
diabetes, levels of physical activity, and alcohol consump-
tion. The 471 controls matched with age were recruited
from Voluntary Bone Marrow Donor (VBMD). Less than
1% of healthy VBMD women come from Maghreb. All
patients were positive for anti-citrullinated peptide antibod-
ies (ACPA) as determined by commercially available ELISA
kits (Orgentec, Hamburg, Germany) and Euroimmun for
Tunisian cases and CCP2 enzyme-linked immuno sorbent
assay (ELISA) (Immunoscan RA, Euro-Diagnostica, Arn-
hem, Netherlands) for French cases.
2.2. Genotyping. Selection for Xq28 polymorphisms from
previously reported SNPs was conducted using the following
criteria: (a) the minor allele frequency (MAF) was >0.05
in the Caucasian population, according to the international
HapMap project databank (http://www.hapmap.org) and to
the NCBI SNP database (https://www.ncbi.nlm.nih.gov), (b)
it was a tagging SNP, and (c) it has been reported to be
associated with RA or other autoimmune diseases in different
populations or other types of studies as GWAS. Genomic
DNA was extracted from total blood leukocytes using stan-
dard methods including proteinase K digestion, followed
by phenol–chloroform extraction and ethanol precipitation.
Finally, all subjects were genotyped for three SNPs (rs1059702
and rs1059703 and rs13397) using direct PCR sequencingwith
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) and an Applied Biosystems (ABI) 3130xL genetic
analyzer (Applied Bio Systems, Foster City, CA, USA). PCR
reactions were performed in a Bio-Rad thermal cycler using
Taq Polymerase (Prim 5 by Fisher Scientific) with initial
denaturing conditions at 96∘C for 5min, followed by 30 cycles
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Table 1: Characteristics of female samples from Tunisian and French cohort.
Characteristic Tunisian population French population
Controls RA patients Controls RA patients
Size of the cohort 131 119 340 289
Age (mean ± SD years) 56.65 ± 17.37 52.16 ± 13.61 46.24 ± 8.92 63.15 ± 20.71
Disease duration (years) NA 15.3 ± 5.6 NA 14.8 ± 6.9
Positive ACPA, 𝑛 (%) NA 119 (100) NA 289 (100)
Positive RF, 𝑛 (%) NA 98 (74.7) NA 200 (69.20)
C-reactive protein (mg/L) NA 12.2 ± 22.7 NA 13.6 ± 21.8
DAS28 NA 6.3 ± 1.2 NA 5.2 ± 1.4
Smoking status% 66 55 76 47
Table 2: Shared epitope frequency and HLA-DRB1 alleles frequency in Tunisian and French RA.
Alleles
HLA-DRB1
Tunisian RA
Allele number
(𝑁 = 264)
Tunisian allele
frequency (%)
French RA
Allele number
(𝑁 = 346)
French allele
frequency (%) OR [95% CI] p value pvalue
∗
#DRB1∗01:XX 16 6.06 59 22.35 0.31 [0–0.51] 1.6𝐸−05 35.2𝐸−05
DRB1∗01:03 0 0.00 1 0.38 0 [0–4.55] 0.32 NS
DRB1∗03:XX 42 15.91 15 5.68 4.17 [2.48–+∞] 1𝐸−06 22𝐸−06
#DRB1∗04:01 11 4.17 48 18.18 0.26 [0–0.47] 1.5𝐸−05 33𝐸−05
DRB1∗04:02 1 0.38 1 0.38 1.31 [0.20–+∞] 0.39 NS
DRB1∗04:03 3 1.14 4 1.52 0.98 [0–3.23] 0.51 NS
#DRB1∗04:04 8 3.03 30 11.36 0.32 [0–0.64] 0.001 0.0022
#DRB1∗04:05 19 7.20 12 4.55 2.15 [1.16–+∞] 0.01 NS
DRB1∗04:06 6 2.27 0 0.00 +∞ [2.49–+∞] 0.002 0.044
DRB1∗04:07 0 0.00 1 0.38 0 [0–4.56] 0.32 NS
#DRB1∗04:08 3 1.14 9 3.41 0.43 [0–1.27] 0.11 NS
DRB1∗04:11 1 0.38 0 0.00 +∞ [0.37–+∞] 0.18 NS
DRB1∗07:XX 41 15.53 46 17.42 1.19 [0.81–+∞] 0.21 NS
DRB1∗08:XX 3 1.14 1 0.38 3.96 [0.68–+∞] 0.11 NS
DRB1∗09:XX 1 0.38 2 0.76 0.65 [0–3.98] 0.41 NS
#DRB1∗10:01 33 12.50 13 4.92 3.65 [2.09–+∞] 2.3𝐸−05 50.6𝐸−05
DRB1∗11:XX 19 7.20 25 9.47 0.99 [0–1.66] 0.5 NS
DRB1∗12:XX 0 0.00 5 1.89 0 [0–0.83] 0.03 NS
DRB1∗13:XX 40 15.15 24 9.09 2.39 [1.52–+∞] 0.0005 0.011
DRB1∗14:XX 4 1.52 4 1.52 1.31 [0.43–+∞] 0.33 NS
DRB1∗15:XX 12 4.55 33 12.50 0.45 [0–0.80] 0.009 NS
DRB1∗16:XX 1 0.38 13 4.92 0.09 [0–0.49] 0.002 0.044
#
Shared epitope, XX means all known alleles, DRB1∗14: XX apart from DRB1∗14:02
∗𝑝 value corrected with Bonferroni correction.
NS: not significant.
of 96∘C for 30 s, 64∘C for 30 s, abd 72∘C for 45 s and a final
extension of 72∘C for 10min.
2.3. HLA-DRB1 Genotyping. Genomic DNA from whole
blood was extracted as described in the subsection
“Genotyping.” HLA-DRB1 typing was carried out according
to the manufacturer’s specification for LAB type SSO HD
(One Lambda Inc., USA) and the retrieved output was
analyzed by HLA Fusion v 1.2.1 software (One lambda Inc.,
USA) for allele information.The following alleles or group of
alleles were genotyped: HLA-DRB1∗01, HLA-DRB1∗01:03,
HLA-DRB1∗03, HLA-DRB1∗04:01, HLA-DRB1∗04:02,
HLA-DRB1∗04:03, HLA-DRB1∗04:04, HLA-DRB1∗04:05,
HLA-DRB1∗04:06, HLA-DRB1∗04:07, HLA-DRB1∗04:08,
HLA-DRB1∗04:11, HLA-DRB1∗07, HLA-DRB1∗08, HLA-
DRB1∗09, HLA-DRB1∗1001, HLA-DRB1∗11, HLA-DRB1∗12,
HLA-DRB1∗13, HLA-DRB1∗14, HLA-DRB1∗15, and HLA-
DRB1∗16 (Table 2).
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2.4. Meta-Analysis Study. A literature search using PubMed,
Science Direct, andWeb of Science databases was conducted
to identify publications that examine the association of
TMEM187 rs13397, IRAK1 rs1059703, IRAK1 rs1059702, and
IRAK1 rs3027898 polymorphisms with RA. Our research
strategy was based on a combination of the following
keywords: variation, variant, polymorphism, SNP, Rheuma-
toid arthritis, RA, TMEM187, IRAK1, rs13397, rs1059703,
rs1059702, and rs3027898. We also reviewed the references
mentioned in the identified articles for any additional rel-
evant studies. Association studies included in our meta-
analyses had to meet the following criteria: (1) evaluation
of association between TMEM187 rs13397, IRAK1 rs1059703,
IRAK1 rs1059702, or IRAK1 rs3027898 polymorphisms and
the susceptibility to RA, (2) use of case-control design, and
(3) inclusion of available genotype frequencies or sufficient
information for calculation. The following information was
extracted from the selected studies: first author, years of
publication, characteristics of cases and controls (mean age,
distribution of gender, and ethnicity), number of cases and
controls, and genotype/allele frequency information. The
strength of the association between the three polymorphisms
and RA was measured by pooled OR with 95% CI. The 𝑍
test was used to determine the significance (𝑝 < 0.05) of the
pooled OR. The heterogeneity between studies was checked
by 𝑄 test and 𝐼2 statistics. We used a fixed effect model when
𝑝 value of the𝑄 test was less than 0.10 or 𝐼2 was equal to or less
than 50%; otherwise, random effect model was used. Finally
this meta-analysis was performed using Review Manager 5.3
software (Cochrane Collaboration, London, UK).
2.5. Statistical Methods. In this study, the Bayesian statistical
method was used to evaluate the confidence intervals (called
in the Bayesian framework credibility intervals) and to
compute the 𝑝 values associated with our tests, as in [20].
Indeed, the Bayesian statisticalmethods aremore appropriate
in case of small samples and the “approximate value” of the
variance of the logarithm of the Odds Ratio. In the Bayesian
framework, the unknown parameter is considered as the
realization of a random variable, which forces us to choose
an a priori probability distribution for that random variable.
We chose an “a priori” distribution for a pair of frequencies
and decided that the two random variables are independent,
each with the probability density equal to 1 on the interval
(0.1). It is fair to say that our prior is uninformative: it is the
uniform distribution on the interval (0.1). The “a posteriori”
distribution of each parameter is easily shown from the Bayes
formula to be a Beta distribution. More precisely, if while
observing 𝑛 realizations of 1 s and 0 s, we get 𝑛 1 s and 𝑛󸀠 0 s,
then the a posteriori distribution of the proportion is the Beta
(𝑛 + 1, 𝑛󸀠 + 1) probability distribution. Since the two samples
come from completely unrelated sources, it is fair to assume
that the two proportions are conditionally independent,
given the data. Consequently a posteriori distribution of
the pair of parameters (corresponding to the proportions of
the given allele among the patients and among the control
individuals) is the product of two Beta distributions whose
density is explicitly known. Our method involves simulating
one million realizations of that pair of random variables,
from which we deduce one million realizations of the Odds
Ratio. The 𝑝 value of the test is then obtained by looking
at which proportion of those values is smaller (resp., larger)
than 1; this gives us 𝑡. Finally we want to discuss the issue
of multiple testing. We have used our Bayesian test method
6 times (Table 5) where the probability of an error among
six successive tests is not controlled by the probability of
an error in each single test. The 𝑝 values were corrected
for multiple comparisons using the Bonferroni correction in
Table 2. PLINK 1.7 version software was used for analysis of
association between haplotypes and disease, and Haploview
4.2 software was used for LD analysis. All haplotypes with
frequencies less than 5% were ignored in analysis. Distribu-
tions of data were tested with the Shapiro-Wilk test. Chi2
or Fisher test was used for categorical data; Yates correction
was performed. For numerical data, comparisons of medians
were performed using Mann–Whitney or Student’s 𝑡-tests.
For correlation study, statistical analyses were performed at
the conventional two-tailed 𝛼 level of 0.05 using R software
version 3.0.2.10. Odds ratios (OR) with 95% confidence
interval (CI) were also calculated. A 𝑝 value less than 0.05
was considered statistically significant.
3. Results
3.1. Demographics and Phenotypes of the Study Subjects.
Characteristics of the 408 ACPA (anti-citrullinated protein
antibody) positive RA and 471 controls from Tunisia and
South Eastern France (Marseille and Montpellier) are shown
in Table 1. All samples were females. The average age was
52 years for the Tunisian RA and 63 years for French RA
women. Age was not significantly different between patients
and control females. There were more presently smokers in
controls than in patients group.
3.2. Frequency of HLA-DRB1 Alleles and SE. Allelic frequen-
cies of the HLA-DRB1 alleles in Tunisian and French RA
patients are presented in Table 2. Due to the size of cohorts,
we applied Bayesian statisticalmethod to define susceptibility
or protective genotypes and calculate accurate confidence
intervals for the associated Odds Ratios. HLA-DRB1∗01,
HLA-DRB1∗03, HLA-DRB1∗04:01, HLA-DRB1∗04:04,
HLA-DRB1∗04:05, HLA-DRB1∗04:06, HLA-DRB1∗10,
HLA-DRB1∗13, HLA-DRB1∗15, and HLA-DRB1∗16 showed
statistical differences between the French and the Tunisian
RA women. No statistical differences were found for
HLA-DRB1∗01:03, HLA-DRB1∗04:02, HLA-DRB1∗04:03,
HLA-DRB1∗04:07, HLA-DRB1∗04:08, HLA-DRB1∗04:11,
HLA-DRB1∗07, HLA-DRB1∗08, HLA-DRB1∗09, HLA-
DRB1∗11, HLA-DRB1∗12, and HLA-DRB1∗14 between both
populations. The RA associated HLA-DRB1 alleles that were
significantly more present in the Tunisian samples compared
to those in the French samples were, by order of Odds Ratios,
HLA-DRB1∗04:05 (OR = 2.15), HLA-DRB1∗13 (OR = 2.39),
HLA-DRB1∗10 (OR = 3.65), HLA-DRB1∗03 (OR = 4.17),
and HLA-DRB1∗04:06 (OR = +∞). Similarly, RA associated
HLA-DRB1 alleles that were significantly more observed in
the French than in the Tunisian samples were, by order of
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Table 3: Shared epitope single dose/double dose frequency in Tunisian and French RA women.
Shared epitope
(SE)
Tunisian RA
𝑁 = 132
Tunisian SE
frequency
(%)
French RA
𝑁 = 173
French SE
frequency
(%)
SE single dose 66 50.00 100 57.80
SE double dose 12 9.09 35 20.34
Total 78 59.09 135 78.48
Table 4: TMEM187-IRAK1 allelic frequencies in samples of RA and healthy controls from Tunisian and French female populations.
Gene/SNPs Populations Alleles Controls (%) RA cases (%)
TMEM 187
rs13397
Tunisian G 207 (79) 178 (75)
A 55 (21) 60 (25)
French G 537 (79) 399 (69)
A 143 (21) 179 (31)
IRAK 1
rs1059703
Tunisian C 57 (22) 69 (29)
T 205 (78) 169 (71)
French C 139 (20) 201 (35)
T 541 (80) 377 (65)
IRAK 1
rs1059702
Tunisian C 196 (75) 167 (70)
T 66 (25) 71 (30)
French C 557 (82) 414 (72)
T 123 (18) 164 (28)
Odds Ratios, HLA-DRB1∗16 (OR = 0.09), HLA-DRB1∗04:01
(OR = 0.26), HLA-DRB1∗01 (OR = 0.31), HLA-DRB1∗04:04
(OR = 0.32), and HLA-DRB1∗15 (OR = 0.45). Three HLA-
DRB1 alleles (DRB1∗04:05, DRB1∗12:XX, and DRB1∗15:XX)
did not show significant differences between Tunisian and
French RA women after the Bonferroni correction.
Two (HLA-DRB1∗04:05 and HLA-DRB1∗10) out of
seven shared SE alleles were overrepresented in the Tunisian
RA population, and three SE alleles (HLA-DRB1∗01, HLA-
DRB1∗04:01, and HLA-DRB1∗04:04) were overrepresented
in the French population. SE single dose showed similar
frequency in both Tunisian and French RA women (50% and
57.80%, resp.), while French RA population displayed higher
SE double dose than Tunisian RA population (20.34% and
9.09%, resp.) (Table 3).
3.3. Association between Three TMEM187-IRAK1 Polymor-
phisms and RA Susceptibility in Women Samples from
Tunisian and French Populations. Genotype distributions of
all three investigated SNPs were in Hardy-Weinberg equi-
librium in both patient and control groups (𝜒2 < 3.84).
Among the genotype frequencies of the three SNPs analyzed
using the dominant modelling, the rs13397 and rs1059703
demonstrated a significant association with RA susceptibility
in both populations. The rs13397 G allele is present in 75%
of RA Tunisian patients and in 69% RA French (Table 4).
The frequency of the rs13397 G major allele was significantly
lower in RA patients than in controls in both Tunisian (OR
0.48 [95% CI 0.12–0.73], 𝑝 = 0.0025) and French (OR =
0.45 [95% CI 0.21–0.59], 𝑝 < 0.001) women populations.
The rs1059703 T major allele was significantly decreased in
patients compared with controls in both Tunisian (OR =
0.46 [95% CI 0.13–0.71], 𝑝 < 0.001) and French (OR =
0.36 [95% CI 0.15–0.47], 𝑝 < 0.001) women populations.
The SNP rs1059702 C showed a significant association with
RA in French patients as compared with control subjects
(OR 1.97 [95% CI 1.22–11.52], 𝑝 < 0.001), but none in
the Tunisian population. Of note, no correlation was found
between polymorphisms and the SE (data not shown).
3.4. Linkage Disequilibrium of TMEM187-IRAK1 Locus with
RA in the Samples of the Tunisian and French Populations. To
determine the extent of linkage disequilibrium (LD) among
the three polymorphisms enclosed in the TMEM187-IRAK1
locus in both Tunisian and French populations, standardized
LD coefficient 𝑟2 was calculated for all pairs of the three
polymorphisms. Our study showed that the IRAK1 SNPs
rs1059703 and rs1059702 did not belong to the same linkage
disequilibrium locus, both in Tunisian and French popula-
tions (Figure 1). We also showed that rs13397 and rs1059703
polymorphisms were in moderate linkage disequilibrium (𝑟2
= 0.5) in the Tunisian population (Figure 1(a)), but not in the
French population (Figure 1(b), 𝑟2 = 0.11).
3.5. Haplotype Analysis. To examine the combined effect of
three variants within the TMEM187-IRAK1 locus, the haplo-
type frequencies defined by the three SNPs rs13397, rs1059703,
and rs1059702 were analyzed. Among the potential hap-
lotypes, four common haplotypes were identified in our
6 Journal of Immunology Research
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Figure 1: Linkage disequilibrium (LD) between TMEM187-IRAK1 SNPs. Correlations (𝑟2 values) among all 3 single nucleotide
polymorphisms (SNPs) located in the TMEM187-IRAK1 locus are indicated in the diamonds for the Tunisian (a) and French (b) populations.
Haploview 4.2 software was used for LD analyses.
Table 5: TMEM187-IRAK1 genotypes for samples of RA and healthy controls in Tunisian and French female populations.
Gene/SNPs Population Genotype Controls(%)
RA cases
(%) OR (95% CI) p values
TMEM 187
rs13397
Tunisian
GG 92 (70) 66 (53)
0.48 (0.12–0.73) 0.0025AG 23 (18) 46 (41)
AA 16 (12) 7 (6)
French
GG 220 (65) 131 (45)
0.45 (0.21–0.59) 1.0𝑒 − 6AG 97 (28) 137 (47)
AA 23 (7) 21 (8)
IRAK 1
rs1059703
Tunisian
CC 15 (11) 9 (7)
0.46 (0.13–0.71) 0.0017CT 27 (21) 51 (43)
TT 89 (68) 59 (50)
French
CC 27 (8) 34 (12)
0.36 (0.15–0.47) 1.0𝑒 − 6CT 85 (25) 133 (46)
TT 228 (67) 122 (42)
IRAK 1
rs1059702
Tunisian
CC 81 (62) 62 (52)
0.67 (0.18–1.02) 0.0608CT 34 (26) 43 (36)
TT 16 (12) 14 (12)
French
CC 237 (70) 157 (54)
0.52 (0.24–0.68) 3.7𝑒 − 5CT 83 (24) 100 (35)
TT 20 (6) 32 (11)
∗𝑝 values compared genotypes according to the dominant/recessive model.
populations with frequencies greater than 5% in both cases
and controls (Table 6).
Results of the analysis suggested that the GTC haplotype,
which carries the rs13397 G variant, displayed a protective
effect against RA in our sample of the French population
(OR = 0.23 (95% CI) [0.16–0.33], 𝑝 < 0.001) while the
ATC, GCC, and GTT haplotypes conferred significant risk
for RA in the same population. French women with the
ATC, GCC, or GTT haplotypes had 3.97-, 2.39-, and 2.05-fold
higher risk of having RA compared to controls. In contrast,
association between all 4 detected haplotypes and disease was
not significant in the sample of the Tunisian women. Overall,
these data further support the involvement of the Xq28 locus
in RA susceptibility in the French population and underscore
ethnical differences.
3.6. Meta-Analysis Study. A meta-analysis was performed
and included datasets from 2076 RA cases and 2112 healthy
controls. To carry out the meta-analysis, we combined our
findings with three independent studies that fit the inclusion
criteria and included a total of 1668 RA patients and 1641
ethnically matched healthy controls from Greece and Korea
[17, 22, 23].The samples size of these studies varied from 119 to
1318 cases and from 131 to 1016 controls.The characteristics of
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Table 6: Association of SNP haplotypes in the TMEM187-IRAK1 region with RA susceptibility.
Chromosome Populations Haplotypes Frequencies OR (95%CI) 𝑝 values Effects
Controls Cases
X
Tunisian [ATC] 0.15 0.15 1.00 (0.63–1.59) 0.995 NA
French 0.09 0.19 3.97 (2.57–6.13) <0.001 Risk
Tunisian [GCC] 0.14 0.17 1.21 (0.79–1.89) 0.379 NA
French 0.06 0.15 2.39 (1.52–3.77) <0.001 Risk
Tunisian [GTT] 0.15 0.18 1.09 (0.70–1.71) 0.692 NA
French 0.04 0.10 2.05 (1.16–3.62) 0.009 Risk
Tunisian [GTC] 0.57 0.50 0.77 (0.57–1.04) 0.083 NA
French 0.68 0.39 0.23 (0.16–0.33) <0.001 Protector
Order of SNPs: [rs13397, rs1059703, rs1059702]
NA: no association.
all studies were summarized in Table 7. Meta-analysis results
showed a significant association between TMEM187 rs13397
(OR = 1.56, 95% CI = 1.25–1.94, and 𝑝 value < 0.0001) and
IRAK1 rs1059702 (OR = 1.41, 95% CI = 1.11–1.80, and 𝑝 value
= 0.006) polymorphisms and susceptibility to RA (Figures
2(a) and 2(c)).The IRAK1 rs1059703 polymorphism showed a
significant protective effect in RA (OR = 0.68, 95% CI = 0.51–
0.89, and𝑝 value = 0.006) (Figure 2(b)).The IRAK1 rs3027898
polymorphism that was available in the three independent
studies fromKorea, China, and Greece showed no significant
association with RA risk (OR = 0.96, 95% CI = 0.67–1.39, and
𝑝 value = 0.83).
4. Discussion
In the present study, we aimed at investigating the association
between three critical polymorphisms in the TMEM187-
IRAK1 locus and risk for ACPApositive RA female patients in
two not previously studied populations: Tunisian and French.
We found that the rs13397 A and rs1059703 C risk alleles
were significantly associated with RA susceptibility for both
populations.The rs1059702 T allele was only found associated
with risk for RA in the French sample. Four haplotypes were
detected in both populations. In the French population, the
major GTC haplotype displayed a protective effect against
RA, whereas the GCC, GTT, and ATC haplotypes conferred
significant increased risk for RA. No association for these
haplotypes was however found in the Tunisian population.
Finally, a strong genetic association of RA susceptibility exists
for the rs13397/rs1059703 block only in women Tunisian
subjects.
Among the many loci that have been identified as asso-
ciated with RA risk using either candidate gene association
studies or GWAS, IRAK1 is the only gene located on the
X chromosome. The IRAK1 gene encodes the interleukin 1
receptor-associated kinase 1, a serine/threonine kinase that
mediates TLRs and IL-1 receptor signaling. Upon recep-
tor stimulation, IRAK1 is recruited, phosphorylated, and
responsible for TLR- and IL1-induced activation of the NF-
𝜅B signaling cascade, thus playing a critical role in the
early inflammatory response [24]. The IRAK1 gene is located
within the Xq28 locus that contains several polymorphisms
associated with increased susceptibility to autoimmunity,
including systemic lupus erythematous [25], systemic sclero-
sis [26, 27], and RA [13, 17, 22, 23]. Altogether, these studies
demonstrated that the Xq28 locus is a shared locus for several
complex diseases, thereby highlighting its role in inflam-
matory disease susceptibility. Recently, two studies devoted
attention to the TMEM187-IRAK1 locus and identified two
SNPs in a Korean population (rs1059702 and rs1059703) [17]
and one SNP (rs13397) in a large cohort of northern European
ancestry [13], respectively, associated with increased disease
susceptibility. In an attempt to investigate new, not previously
studied populations and to replicate the above studies, we
examined the distribution of these three SNPs and found
statistical differences between RA patients and controls for
both Tunisian and French populations. Although risk alleles
for both rs1059702 and rs1059703 were different, they were
also associated with risk for RA in both Tunisian and
French populations. Indeed, the rs1059702 T and rs1059703 C
polymorphismswere in strong associationwith RA inKorean
women while we found the rs1059702 C and rs1059703 T
alleles in our cohorts. In agreement with the study of Eyre
et al. [13], we found the minor rs13397 A allele to be the
risk allele in both the French and Tunisian cohorts. Earlier
work performed on a small Greek cohort found no associ-
ation between the rs1059703 and RA [22]. These differences
might have several explanations, including the sample size
of cohorts used, the Bayesian statistical method being better
suited than the SPSS statistical package to decide about
susceptibility in small samples, the classification criteria used
to select RA patients (ACR 1987 versus 2010 ACR/EULAR
that discriminate or not betweenACPApositive RApatients),
and different ethnic and regional populations.
Concerning the haplotype and LD studies, we are the first
to study the combination of LD and haplotypes of these three
SNPs with RA. We found that, with the exception of rs13397
and rs1059703 polymorphisms, which were in moderate
linkage disequilibrium in the Tunisian population (𝑟2 = 0.5),
other polymorphisms were not in linkage disequilibrium in
both population. This finding seems to be in contradiction
with the Korean study that previously reported a linkage
disequilibrium block on Xq28 enclosing both rs1059702 and
rs1059703 [17]. Discrepancies between Korean, Tunisian, and
French populations might be due to differences in genetic
background. Interestingly, a comparative study reported that
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Total (95% CI) 816 942 100% 1.56 [1.25, 1.94]
Total events 239 198
Heterogeneity: 𝜒2 = 1.29, df = 1 (p = 0.26); I2 = 23%
Test for overall effect: Z = 4.00 (p < 0.0001)
(a)
France (this study) 377 578 541 680 27.2% 0.48 [0.37, 0.62]
Greece (Chatzikyriakidou et al. 2010) 206 272 234 294 20.6% 0.80 [0.54, 1.19]
Korea (Han et al. 2013) 507 2326 441 1714 32.0% 0.80 [0.70, 0.93]
Tunisia (this study) 169 238 205 262 20.2% 0.68 [0.45, 1.02]
3414 2950 100% 0.68 [0.51, 0.89]
1259 1421
Favours [control]Favours [experimental]
Cases Controls Odds Ratio Odds RatioStudy or subgroup Events Total Events Total
Weight
M-H, random, 95% CI M-H, random, 95% CI
Total (95% CI)
Total events 
Test for overall effect: Z = 2.75 (p = 0.006)
Heterogeneity: 𝜏2 = 0.06, 𝜒2 = 12.20, df = 3 (p = 0.007); I2 = 75% 0.01 0.1 101 100
(b)
164 578 123 680 32.7% 1.79 [1.37, 2.34]
1807 2324 1266 1720 45.0% 1.25 [1.08, 1.45]
71 238 66 262 22.4% 1.26 [0.85, 1.87]
3140 2662 100.0% 1.41 [1.11, 1.80]
2042 1455
France (this study)
Korea (Han et al. 2013)
Tunisia (this study)
Favours [control]Favours [experimental]
Cases Controls Odds Ratio Odds RatioStudy or subgroup
Events Total Events Total
Weight
M-H, random, 95% CI M-H, random, 95% CI
Total (95% CI)
Total events 
Test for overall effect: Z = 2.77 (p = 0.006)
0.01 0.1 101 100Heterogeneity: 𝜏
2 = 0.03, 𝜒2 = 5.50, df = 2 (p = 0.06); I2 = 64%
(c)
Figure 2: Forest plot of the association between TMEM187 rs13397 (a), IRAK1 rs1059703 (b), and IRAK1 rs1059702 (c) polymorphisms and
RA. Meta-analyses were performed for the rs13397 (a), rs1059703 (b), and rs1059702 (c) polymorphisms, respectively, using Review Manager
5.3 software.
none of the susceptibility loci identified by GWAS in Cau-
casian patients with RA contributed significantly to disease
in Koreans [28].
We found differences between French and Tunisian pop-
ulations for association of SNP haplotypes in the TMEM187-
IRAK1 locus with RA susceptibility. The CTG haplotype
displayed a protective effect against RA, while the ATC, GCC,
and GTT haplotypes conferred significant susceptibility to
RA, in French women. All four haplotypes showed no
association in the Tunisian women sample. In both Tunisian
and French cohorts, we found the GTC common haplotype
in 57 and 68% of the control populations, respectively. This
GTC haplotype carries the major alleles for the three SNPs
rs13397 G, rs1059703 T, and rs1059702 C.
Although alleles and haplotypes identified among
Tunisian and French subjects display differences with
previous studies performed with Korean and northern
European cohorts, our present work confirms significant
association of the three SNPs with RA susceptibility. The
minor discrepancy found for the rs1059702 in the Tunisian
RA women populationmight be due to the size of the cohort.
Indeed, pooled results for the three different ethnical groups
including Tunisian confirm a significant association between
rs1059702 and risk for RA.
Our meta-analysis including a larger case-control data
set of two independent studies from Korea and Greece in
addition to our data sets confirmed that TMEM187 rs13397,
IRAK1 rs1059702, and IRAK1 rs1059703 are associated with
RA. Unfortunately, data sets on the TMEM187 rs13397 from
populations of European ancestry [13] were not available
for inclusion in our meta-analysis. The IRAK1 rs3027898
that was not investigated in our study but available in the
three independent studies from Korea, China, and Greece
showed no significant association in the meta-analysis (data
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not shown). To the best of our knowledge, this is the first
meta-analysis study on the association between RA and these
four polymorphisms in TMEM187-IRAK1.
Many studies have documented that one of the key
genetic elements closely linked to RA susceptibility is the
HLA complex locus located in the chromosome 6 [15]. Our
present study evaluated the frequency ofHLA-DRB1 alleles in
Tunisian and French RAwomen, all ACPA positive, and con-
firmed that both populations belonging to different ethnical
groups do not share the same HLA susceptibility alleles. As
expected for the French population, we find the usual associa-
tion between RA andHLA-DRB1∗01, HLA-DRB1∗04:01, and
HLA-DRB1∗04:04 [20]. We show that two SE alleles, HLA-
DRB1∗04:05 and HLA-DRB1∗10, are overrepresented in the
RA Tunisian population.This is in agreement with a previous
report showing their association with RA susceptibility in
Tunisia [19].TheHLA-DRB1∗04 allele has also been reported
in RApopulations fromMorocco [29], Saudi Arabia [30], and
Turkey [31].TheHLA-DRB1∗10 allele has been reported to be
associatedwith RA in Saudi Arabia [30], Italy [32], Spain [33],
Turkey [34], and Asian Indian [35] populations.
A meta-analysis performed in Latin America RA pop-
ulation (Colombia, Peru, Brazil, Argentina, Mexico, and
Chili) showed that HLA-DRB1∗04:04 allele is associated
with disease risk [36]. Moreover, this whole genome scan
study also shows that the second most consistently linked
region to RA is the Xq28 locus. The absence of the HLA-
DRB1∗01:03, HLA-DRB1∗04:07, and HLA-DRB1∗12 alleles
in our RA Tunisian population sample is in accordance with
the protective effect suggested by previous study [19]. Con-
sidering the observed differences between ethnical groups
for HLA-DRB1, our findings suggest that the association of
the TMEM187-IRAK1 locus with RA risk may play a role
independently of the major genetic risk locus for RA.
5. Conclusion
In conclusion, the present study illustrates the involvement
of the Xq28 locus in RA susceptibility in both Tunisian and
French populations with ethnical differences. Finally, the
meta-analysis combining our findings with two independent
studies from Greece and Korea further supports the fact that
the three polymorphisms are important in the susceptibility
for RA. Although a growing number of studies suggest the
contribution of the X chromosome to RA, as to many other
autoimmune diseases, future works shall be performed to
compare female and male RA populations to identify the
exact contribution of this locus, with a focus on TMEM187-
IRAK1 polymorphisms. Furthermore, functional studies on
the impact of these polymorphisms on both gene expressions
in RA populations might help defining new therapeutic
perspectives in RA.
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